Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates
Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of -374.68% and -23.18%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?